Skip to Main Content

Paper Details

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
J Infect Dis
64
2021

Datasets

Release 1.2